selected scholarly activity
-
conferences
- Schizophrenia and Delusional Disorder: Useful Distinctions in the Late-Onset Population?. Biological Psychiatry. 212S-212S. 2009
- Caffeine and nicotine independently protect against haloperidol-induced downregulation of midbrain dopamine neurons. Annals of Neurology. S54-S54. 2006
- Microglial activation may mediate the toxic effects of haloperidol on midbrain dopamine neurons. Annals of Neurology. S78-S78. 2006
- Treatment of conversion disorder. PSYCHOGENIC MOVEMENT DISORDERS: NEUROLOGY AND NEUROPSYCHIATRY. 289-+. 2006
- Rapid induction of proapoptotic proteins in nigral dopamine neurons by antipsychotic medication. Annals of Neurology. S42-S42. 2003
- Evidence that antipsychotic drugs and 3-nitroproprionic acid independently induce cell death in midbrain dopamine neurons by activation of the apoptosis cascade. Annals of Neurology. S85-S86. 2002
- Postconcussion syndrome is accompanied by prolonged latencies of visual evoked responses. Annals of Neurology. S28-S28. 2002
- Can neuroleptic drugs cause Parkinson's disease?. Annals of Neurology. 478-478. 1999
- Extrapyramidal side-effects of risperidone. Neurology. 5131-5131. 1997
- DIURNAL-VARIATION IN ACUTE NEUROLEPTIC-INDUCED DYSTONIA. Annals of Neurology. 299-300. 1995
- POSITRON EMISSION TOMOGRAPHY SCAN STUDIES IN A PRIMATE MODEL OF STRIATAL DEGENERATION - IMPLICATIONS FOR THE MITOCHONDRIAL HYPOTHESIS OF HUNTINGTONS-DISEASE. Annals of Neurology. 316-316. 1994
- RELATIONSHIP BETWEEN PRIMARY DIAGNOSIS AND RESPONSIVENESS TO LORAZEPAM IN PATIENTS PRESENTING TO A PSYCHIATRY SERVICE WITH CATATONIA. Annals of Neurology. 279-280. 1994
- NEUROPEPTIDE ABNORMALITIES IN CEREBRAL-CORTEX OF OLIVOPONTOCEREBELLAR ATROPHY POSTMORTEM BRAIN. Annals of Neurology. 271-272. 1992
- CHOLECYSTOKININ IMMUNOREACTIVITY IN HUNTINGTONS-DISEASE - WIDESPREAD INCREASES IN POSTMORTEM CEREBRAL-CORTEX. NEUROPEPTIDE CHOLECYSTOKININ ( CCK ). 28-32. 1989
- REDUCED CONCENTRATIONS OF VASOPRESSIN IN THE SUBSTANTIA NIGRA PARS COMPACTA IN POSTMORTEM PARKINSONS-DISEASE BRAIN. Annals of Neurology. 148-148. 1988
- SOMATOSTATIN, NEUROPEPTIDE-Y AND VASOACTIVE INTESTINAL PEPTIDE IN HUNTINGTONS-DISEASE - NO RELATIONSHIP BETWEEN NEUROPEPTIDE LEVELS AND DEGREES OF TISSUE ATROPHY. Canadian Journal of Neurological Sciences. 200-200. 1988
- CORTICOTROPIN-RELEASING FACTOR AND SOMATOSTATIN IN ALZHEIMERS-DISEASE - COMPARATIVE CHANGES IN POSTMORTEM CEREBRAL-CORTEX. Annals of Neurology. 122-123. 1987
- NEUROPEPTIDE-Y IS INCREASED IN HUNTINGTONS-DISEASE. Annals of Neurology. 152-152. 1986
- VASOACTIVE-INTESTINAL-PEPTIDE IMMUNOREACTIVITY IN ALZHEIMER CEREBRAL-CORTEX. Annals of Neurology. 126-126. 1986
- OXYTOCIN IN POSTMORTEM ALZHEIMER BRAIN. Neurology. 271-271. 1986
- SUBSTANCE P-LIKE IMMUNOREACTIVITY IS REDUCED IN CEREBRAL-CORTEX IN ALZHEIMERS-DISEASE. Neurology. 273-273. 1986
- SOMATOSTATIN-LIKE IMMUNOREACTIVITY IN ALZHEIMERS-DISEASE. Annals of Neurology. 144-144. 1985
- VASOPRESSIN IN POSTMORTEM ALZHEIMER BRAIN. Annals of Neurology. 143-144. 1985
- VASOPRESSIN RELEASE INTO THE PLASMA OF THE RAT INDUCED BY ENDOTOXIN - A NOVEL STIMULUS. Canadian Journal of Physiology and Pharmacology. AR16-AR17. 1984
- VASOPRESSIN AND INAPPROPRIATE ANTI-DIURESIS IN ACUTE NEUROVASCULAR ILLNESS. Canadian Journal of Neurological Sciences. 297-297. 1982
- INAPPROPRIATE ANTI-DIURESIS AND THE DETERIORATING STROKE. Annals of Neurology. 104-104. 1981
-
journal articles
- Does early antipsychotic response predict long‐term treatment outcome?. Human Psychopharmacology. 32. 2017
- Mental illness in patients with inherited mitochondrial disorders. Schizophrenia Research. 187:33-37. 2017
- The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects. Journal of Clinical Psychopharmacology. 37:8-12. 2017
- The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine. Psychiatry Research. 241:72-77. 2016
- Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology. WORLD JOURNAL OF PSYCHIATRY. 6:391-391. 2016
- Cushing Disease Presenting as Primary Psychiatric Illness. Journal of Psychiatric Practice. 21:449-457. 2015
- Metabolite measurements in the caudate nucleus, anterior cingulate cortex and hippocampus among patients with mitochondrial disorders: a case-control study using proton magnetic resonance spectroscopy. CMAJ open. 1:E48-E55. 2013
- Psychiatric symptoms correlate with metabolic indices in the hippocampus and cingulate in patients with mitochondrial disorders. Translational Psychiatry. 2:e187-e187. 2012
- The Psychiatric Presentation of Mitochondrial Disorders in Adults. Journal of Neuropsychiatry and Clinical Neurosciences. 24:394-409. 2012
- The mitochondrial genome and psychiatric illness. American Journal of Medical Genetics, Part B, Neuropsychiatric Genetics. 159B:749-759. 2012
- The comparative effects of environmental enrichment with exercise and serotonin transporter blockade on serotonergic neurons in the dorsal raphe nucleus. Synapse. 66:465-470. 2012
- The Psychiatric Manifestations of Mitochondrial Disorders. Journal of Clinical Psychiatry. 73:506-512. 2012
- Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra. Synapse. 65:1166-1172. 2011
- Role of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neurons. Brain Research. 1394:24-32. 2011
- Treatment of Conversion Disorder in the 21st Century: Have We Moved Beyond the Couch?. Current Treatment Options in Neurology. 13:255-266. 2011
- Resolution of Catamenial Epilepsy after Goserelin Therapy and Oophorectomy: Case Report of Presumed Cerebral Endometriosis. Journal of Minimally Invasive Gynecology. 18:128-130. 2011
- Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CANADIAN MEDICAL ASSOCIATION JOURNAL. 182:E834-E838. 2010
- Role of serotonin transporter inhibition in the regulation of tryptophan hydroxylase in brainstem raphe nuclei: time course and regional specificity. Neuroscience. 171:407-420. 2010
- Role of AP-2α Transcription Factor in the Regulation of Synapsin II Gene Expression by Dopamine D1 and D2 Receptors. Journal of Molecular Neuroscience. 41:267-277. 2010
- Catatonia and Its Treatment. Schizophrenia Bulletin. 36:239-242. 2010
- Treating Psychiatric Illness in Patients With Mitochondrial Disorders. Journal of the Academy of Consultation-Liaison Psychiatry. 51:179-179. 2010
- Neuroleptic Malignant Syndrome and the Acute Phase Response. Journal of Clinical Psychopharmacology. 28:459-461. 2008
- The Neuropsychiatric Profile of Addison's Disease: Revisiting a Forgotten Phenomenon. Journal of Neuropsychiatry and Clinical Neurosciences. 18:450-459. 2006
- The Neuropsychiatric Profile of Addison’s Disease: Revisiting a Forgotten Phenomenon. Journal of Neuropsychiatry and Clinical Neurosciences. 18:450-459. 2006
- Recognizing neuroleptic malignant syndrome. CANADIAN MEDICAL ASSOCIATION JOURNAL. 170:1645-1645. 2004
- Tardive dystonia and its treatment. Journal of Psychiatry & Neuroscience. 28:240-240. 2003
- Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone. Neurology. 55:1069-1069. 2000
- Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone - Reply. Neurology. 54:1543-1544. 2000
- Magnetic Resonance Imaging Abnormalities and Psychiatric Illness. American Journal of Psychiatry. 157:306-307. 2000
- Reply. Movement Disorders. 15:180-181. 2000
- The Neuropsychiatry of Adult-Onset Adrenoleukodystrophy. Journal of Neuropsychiatry and Clinical Neurosciences. 11:315-327. 1999
- Late-Onset Adrenoleukodystrophy Associated With Long-Standing Psychiatric Symptoms. Journal of Clinical Psychiatry. 60:460-468. 1999
- Serotonin Syndrome as a Result of Clomipramine Monotherapy. Journal of Clinical Psychopharmacology. 19:285-287. 1999
- Catatonia: Re-awakening to a forgotten disorder. Movement Disorders. 14:395-397. 1999
- Catatonia Following Gabapentin Withdrawal. Journal of Clinical Psychopharmacology. 19:188-189. 1999
- Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 52:782-782. 1999
- Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal. Journal of Neurology, Neurosurgery and Psychiatry. 64:799-801. 1998
- Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience. 84:201-211. 1998
- Neuropsychiatric Aspects of the Adult Variant of Tay-Sachs Disease. Journal of Neuropsychiatry and Clinical Neurosciences. 10:10-19. 1998
- Role of glutamate receptor subtypes in the differential release of somatostatin, neuropeptide Y, and substance P in primary serum-free cultures of striatal neurons. Synapse. 27:161-167. 1997
- The ontogeny of NADPH-diaphorase neurons in serum-free striatal cultures parallels in vivo development (vol 76, pg 1221, 1997). Neuroscience. 78:613-&. 1997
- The ontogeny of NADPH-diaphorase neurons in serum-free striatal cultures parallels in vivo development.. Neuroscience. 78:615-624. 1997
- Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Annals of Neurology. 41:540-547. 1997
- Protracted akathisia after risperidone withdrawal. American Journal of Psychiatry. 154:437b-438. 1997
- The ontogeny of NADPH-diaphorase neurons in serum-free striatal cultures parallels in vivo development. Neuroscience. 76:1221-1230. 1997
- Dopamine–glutamate interactions in the striatum: behaviourally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms. Neuroscience. 75:1065-1074. 1996
- Catatonia After Benzodiazepine Withdrawal. Journal of Clinical Psychopharmacology. 16:315-319. 1996
- Circadian pattern of acute, neuroleptic-induced dystonic reactions. American Journal of Psychiatry. 153:708-710. 1996
- Behavioral Characterization of Quinolinate-Induced Lesions of the Medial Striatum: Relevance for Huntington's Disease. Experimental Neurology. 138:158-168. 1996
- Complicating Factors in the Analysis of Acute Drug-Induced Akathisia. JAMA psychiatry. 52:878-878. 1995
- Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues.. Journal of Clinical Psychiatry. 56:347-353. 1995
- Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers.. Journal of Clinical Psychiatry. 55:20-23. 1994
- Reduced cerebral cortical but elevated striatal concentration of somatostatin-like immunoreactivity in dominantly inherited olivopontocerebellar atrophy.. Journal of Neurology, Neurosurgery and Psychiatry. 56:1013-1015. 1993
- Do benzodiazepines modify the incidence of neuroleptic-induced dystonia?. American Journal of Psychiatry. 150:528-529. 1993
-
The cortical lesion of Huntington's disease: Further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N‐methyl‐
D ‐aspartate lesions of rat cortex. Annals of Neurology. 32:526-534. 1992 - The Treatment of Catatonia: Benzodiazepines or ECT?. American Journal of Psychiatry. 149:1279-1279. 1992
- The Treatment of Neuroleptic Malignant Syndrome are Dantrolene and Bromocriptine Useful Adjuncts to Supportive Care?. The British journal of psychiatry. Supplement. 159:709-712. 1991
- Iron in neuroleptic malignant syndrome. The Lancet. 338:820-821. 1991
- Serum iron and neuroleptic malignant syndrome. The Lancet. 338:149-151. 1991
- Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex. Neurology. 41:716-719. 1991
- A CONSIDERATION OF THE MECHANISMS BY WHICH LORAZEPAM MIGHT TREAT CATATONIA - REPLY. Journal of Clinical Psychiatry. 52:187-188. 1991
- MPTP-Induced Neurotoxicity and the Quest for a Preventative Therapy for Parkinson's Disease. Canadian Journal of Neurological Sciences. 18:77-82. 1991
- Bromocriptine and neuroleptic malignant syndrome.. Journal of Clinical Psychiatry. 52:41-42. 1991
- LOW SERUM IRON LEVELS AND NEUROLEPTIC MALIGNANT SYNDROME - REPLY. American Journal of Psychiatry. 148:148-149. 1991
- Neurochemical characterization of excitotoxin lesions in the cerebral cortex. Journal of Neuroscience. 11:147-158. 1991
- Tardive Dyskinesia and the Law. Canadian Journal of Psychiatry. 35:573-574. 1990
- Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam.. Journal of Clinical Psychiatry. 51:357-362. 1990
- Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits. Neuroscience. 29:339-346. 1989
- Galanin‐Like Immunoreactivity Is Unchanged in Alzheimer's Disease and Parkinson's Disease Dementia Cerebral Cortex. Journal of Neurochemistry. 51:1935-1941. 1988
- Hypophysiotrophic function of vasopressin and oxytocin. Brain Research Bulletin. 20:729-736. 1988
- Somatostatin and neuropeptide Y concentrations in pathologically graded cases of huntington's disease. Annals of Neurology. 23:562-569. 1988
- A detailed examination of substance P in pathologically graded cases of Huntington's disease. Journal of the Neurological Sciences. 84:51-61. 1988
- Cerebrospinal Fluid Somatostatin and Neuropeptide Y. JAMA Neurology. 45:269-269. 1988
- Somatostatin and neuropeptide Y immunoreactivity in parkinson's disease dementia with alzheimer's changes. Synapse. 2:463-467. 1988
- The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer's disease striatum. Neuroscience Letters. 79:201-206. 1987
- Substance P‐like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology. 37:1205-1205. 1987
- Oxytocin in Alzheimer's disease. Neurology. 37:1001-1001. 1987
- A comparison of somatostatin and neuropeptide Y distribution in monkey brain. Brain Research. 405:213-219. 1987
- AMINO ACID NEUROTRANSMITTER ABNORMALITIES IN HUNTINGTON'S DISEASE AND THE QUINOLINIC ACID ANIMAL MODEL OF HUNTINGTON'S DISEASE. Brain. 110:1657-1673. 1987
- Neuropeptides in Alzheimer's disease.. Journal of Neural Transmission, Supplement. 24:163-174. 1987
- Vasopressin in Alzheimer's disease: A study of postmortem brain concentrations. Annals of Neurology. 20:665-670. 1986
- A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Annals of Neurology. 20:616-621. 1986
- Neuropeptides in Alzheimer's Disease: Clinical implications. Neurologic Clinics. 4:753-768. 1986
- Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Research. 397:386-388. 1986
- Widespread reduction of somatostatin‐like immunoreactivity in the cerebral cortex in Alzheimer's disease. Annals of Neurology. 20:489-495. 1986
- Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Annals of Neurology. 20:282-288. 1986
- CSF vasopressin concentration is reduced in Alzheimer's disease. Neurology. 36:1133-1133. 1986
- Reduced concentrations of arginine vasopressin and MHPG in lumbar CSF of patients with Korsakoff's psychosis. Life Sciences. 38:2301-2306. 1986
- Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:168-171. 1986
- Somatostatin-281–12-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Brain Research. 368:380-383. 1986
- An examination of neuropeptide Y postmortem stability in an animal model simulating human autopsy conditions. Neuroscience Letters. 64:69-74. 1986
- CSF somatostatin‐like immunoreactivity in dementia. Neurology. 36:294-294. 1986
- Somatostatin Binding Sites in Human and Monkey Brain: Localization and Characterization. Journal of Neurochemistry. 46:359-365. 1986
- Somatostatin: alterations in the central nervous system in neurological diseases.. Research publications - Association for Research in Nervous and Mental Disease. 64:215-257. 1986
- Human cerebrospinal fluid somatostatin in neurologic disease. Journal of the Neurological Sciences. 71:91-104. 1985
- Reduced Numbers of Somatostatin Receptors in the Cerebral Cortex in Alzheimer's Disease. Science. 229:289-291. 1985
- Endotoxin increases vasopressin release independently of known physiological stimuli. American Journal of Physiology. 248:E420-E424. 1985
- ENDOTOXIN INCREASES VASOPRESSIN RELEASE INDEPENDENTLY OF KNOWN PHYSIOLOGICAL STIMULI. American Journal of Physiology. 248:E420-E424. 1985
- INAPPROPRIATE ANTI-DIURESIS AND THE DETERIORATING STROKE. Transactions of the American Neurological Association. 106:346-348. 1981